Serum neurofilament level as a biomarker in multiple sclerosis

Abstract

Background & Objective: Currently, MS disease activity and neurodegeneration are assessed mainly through clinical evaluation and magnetic resonance imaging. These measures lack sensitivity and specificity, leading to a constant search for a new biomarker. Several markers have been studied, and the most promising to date is the neurofilament. Our objective was to examine the relationship between serum neurofilament levels and multiple sclerosis parameters.

Methods: Fifty-six adults who fulfilled the McDonald’s criteria 2017 for the diagnosis of MS, and forty-four healthy controls were enrolled in this study. Serum samples were collected to assess neurofilament light and heavy chain (NfL & NfH) levels using the ELISA method, the results were compared for MS patients and controls; and were also correlated to the type of MS, disease duration, EDSS (expanded disability status scale), MSSS (MS severity score) and disease activity.

Results: The mean serum NfL and NfH levels for cases were 133.3 pg/ml and 3654.5 pg/ml respectively, which are significantly higher than that for controls (NfL = 80 pg/ml; and NfH = 408.8 pg/ml; p-value < 0.001). There were no significant correlations between serum neurofilament levels and EDSS, MSSS, disease activity, type, and duration.

Conclusions: In our study, we could not find a significant role for the ELISA neurofilament serum level as a biomarker for MS disease activity and severity.